Drugs and patents in ATC class A04AD

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
METHSCOPOLAMINE BROMIDE	methscopolamine bromide
PAMINE	methscopolamine bromide
PAMINE FORTE	methscopolamine bromide
SCOPOLAMINE	scopolamine
TRANSDERM SCOP	scopolamine
>Tradename	>Generic Name

Last updated: April 26, 2026

How big is the A04AD “Other antiemetics” market and how is it moving?

ATC A04AD is a small, heterogeneous bucket within antiemetics. It captures “other” agents that do not fall cleanly into metoclopramide (A03FA), 5-HT3 antagonists (A04AA), NK1 antagonists (A04A A?), corticosteroids (A04AD? varies by classification), or others. The practical result for market dynamics is fragmentation: each sub-therapy competes for different indications (chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), gastroparesis-related nausea, migraine-associated nausea, pregnancy-related nausea, and radiation-induced nausea).

Market drivers by use case

CINV protocols are the primary volume engine. The center of gravity in oncology supportive care is standardized multi-agent regimens where newer add-ons win on marginal efficacy or reduced breakthrough rates.
PONV is a second volume engine where combination prophylaxis is common and where oral, sublingual, or parenteral convenience matters.
Non-oncology nausea is more fragmented and more sensitive to local practice, formularies, and route of administration.

What “Other antiemetics” tends to capture commercially Within A04AD, commercially relevant products typically include non-core antiemetic mechanisms (not pure 5-HT3, not pure NK1, not pure dopamine antagonist core). That changes the competitive math:

Brand vs. generic pressure varies by molecule. Some A04AD entries face early generic erosion; others are protected by newer chemical entities or reformulations.
Formulation often matters more than mechanism. Rapid onset, oral bioavailability, fixed-dose combinations, and rescue dosing options can shift share even against generics.

Which molecules define A04AD competitiveness?

A04AD’s competitiveness depends on which specific active ingredients your jurisdiction codes into “Other antiemetics.” Without a jurisdiction-specific ATC-to-ingredient mapping, the patent landscape must be handled at two levels: 1) Class-level dynamics (where the category competes in oncology supportive care and PONV protocols) 2) Molecule-level patent cliffs (where each active ingredient’s patent estate determines the pathway for generic and biosimilar-like competitive dynamics)

Because “A04AD” is an ATC bucket, a complete, accurate patent landscape requires the exact list of ATC A04AD active ingredients and their marketed forms by geography. That mapping is not contained in the prompt, and producing it from memory risks material errors.

What are the patent risks and timing for A04AD generally?

Even without a molecule roster, the patent landscape for “other antiemetics” follows repeatable patterns seen across modern antiemetic development:

1) Primary patent term is often complemented by secondary protections

Polymorphs/solid forms for tablets or orally disintegrating formulations
Crystalline forms, solvates, amorphous forms
Combinations (fixed dose combinations with core antiemetics)
Method-of-use patents targeted to CINV or PONV regimens (e.g., dosing schedules, patient stratification, emetogenic risk categories)
Route-of-administration claims (oral vs parenteral; subcutaneous vs IV)
Patient selection claims based on risk scores or prior regimen exposure

2) Patent cliffs tend to concentrate around mature CINV standards In CINV, treatment guidelines evolve. When guidelines lock in a multi-agent regimen, method-of-use claims are more likely to survive for longer if they remain consistent with standard prophylaxis.

3) Generic entry pathways

ANDA-style generics (small molecule) after composition and method-of-use protection expires
Label carve-outs to avoid infringement of method-of-use claims
Switch to non-infringing indication or dosing is common if method-of-use claims remain active

4) Litigation is typically strategy-driven A04AD participants often face:

Paragraph IV certifications where generic manufacturers challenge one or more listed patents in the originator’s bundle (US model)
Settlement-based entry with date-certain approvals
“Evergreening” disputes around secondary formulation and method-of-use patents

What does the enforcement landscape look like (US/EU dynamics)?

For antiemetics in established care settings, patent enforcement in the US typically hinges on Orange Book-listed patents and their expiration:

Composition-of-matter patents: hardest to work around; claim scope can be decisive
Method-of-use patents: may allow generic “design around” via label and regimen changes
Formulation patents: can block substitution if manufacturing depends on protected solid-state forms

In the EU, enforcement is more jurisdiction-specific and often includes:

Validation of national patents and injunction strategy
Assessment of claim scope under local claim construction practices
EPO opposition outcomes affecting national enforceability

Where are “other antiemetics” most exposed to competitive substitution?

A04AD is exposed when:

The molecule’s clinical value is incremental relative to core antiemetics (5-HT3, NK1, dopamine antagonists, olanzapine where applicable), letting payers prefer cheaper alternatives
The product is used in broad prophylaxis where guidelines do not strictly require that specific agent
The route of administration is hard to defend (generic bioequivalence is easier where a simple formulation exists)
Method-of-use claims are narrow and become irrelevant as standard-of-care changes

It is more protected when:

The agent is part of specific CINV risk-based algorithms that prescribers follow closely
The product has a differentiated onset or dosing convenience that becomes a practical standard
Patents cover fixed-dose combinations or specific solid-state forms used at scale

What is the patent landscape structure for A04AD (what to look for)?

A complete A04AD patent map should be structured around four layers:

1) Composition of matter

Core chemical entity patents
Key analog series patents (if claims cover broad structural classes)

2) Solid-state and formulation

Polymorph/crystal/solvate claims
Film coating or excipient compositions (less common but possible)
Orally disintegrating or modified release manufacturing patents

3) Regimen and method-of-use

CINV cycle-day or fraction-day timing
Breakthrough nausea rescue schedules
Risk stratification (high vs moderate emetogenicity)

4) Regulatory exclusivity and lifecycle

Hatch-Waxman protections (US) where relevant
Supplementary protection certificates (SPCs) in the EU
Pediatric extensions where they apply

What is the practical implication for R&D investment decisions?

A04AD development economics generally come down to whether the program can deliver one of these:

A differentiated regimen position that supports long-lived method-of-use claims
A formulation or solid-state advantage that is defensible against easy generic substitution
A combination logic that becomes standard and preserves label-based protection

If the drug’s clinical differentiation is limited and standard practice already uses cheaper core agents, A04AD entrants face fast payer-driven substitution even with meaningful efficacy in trials.

Key patent-execution issues that determine generic speed

For A04AD molecules that survive to launch:

Patent list completeness in key jurisdictions (composition, solid form, method-of-use, and combinations)
Claim defensibility after opposition/challenge
Infringement-proofing for formulation and method claims (manufacturing evidence, stability data, regimen alignment)
Design-around feasibility (alternate solid forms, alternate dosing schedules, label amendments)

Key takeaways

ATC A04AD is a fragmented “other” bucket, so market dynamics are driven less by class-wide growth and more by molecule-by-molecule differentiation in CINV and PONV protocols.
The patent landscape for A04AD typically depends on secondary protections (solid state, combinations, and method-of-use) because incremental efficacy against core antiemetics accelerates substitution risk.
The decisive investment questions are whether the asset can secure long-lived regimen position and formulation defensibility that slows label and manufacturing substitution by generics.
Competitive exposure rises when guidelines do not require the specific A04AD agent or when method-of-use claims are narrow and can be avoided via label changes.

FAQs

1) Is ATC A04AD dominated by a single mechanism (like 5-HT3 or NK1)?
No. A04AD is heterogeneous, and the commercial balance depends on which “other” mechanisms each molecule represents and how it fits into CINV and PONV regimens.

2) What protects A04AD products from rapid generic entry?
Protection typically comes from a combination of composition-of-matter plus secondary patents covering solid forms, combinations, and regimen-specific method-of-use claims.

3) Where do method-of-use patents matter most for this class?
They matter most when prescribers follow fixed prophylaxis or rescue protocols that align with the claimed dosing schedules and patient risk categories.

4) Why can payer substitution happen even when clinical efficacy is meaningful?
When the drug is an incremental add-on within standardized multi-agent regimens, payers often prefer lower-cost alternatives if the agent is not required by guidelines.

5) What is the most common route for generic design-around in A04AD?
Label carve-outs and regimen changes that avoid infringement of method-of-use patents, paired with non-infringing formulation choices if solid-state patents are narrow.

References

[1] WHO. ATC classification system and ATC/DDD methodology. World Health Organization. https://www.whocc.no/atc_ddd_index/

Drugs in ATC Class A04AD

Drugs in ATC Class: A04AD - Other antiemetics

ATC Class A04AD (Other Antiemetics): Market Dynamics and Patent Landscape